Dogs were administered conventional treatments with or
without pimobendan.
Not exact matches
In the EPIC Study, dogs in the
pimobendan group experienced 10 % more life
without congestive heart failure (CHF) signs that impact quality of life (10 % more life
without CHF was calculated based on an estimated lifespan for all small to medium ‑ sized dogs being 12.5 years.
As a positive inotrope,
pimobendan acts directly on the heart, increasing cardiac output and tissue perfusion
without increasing energy or oxygen consumption.4, 5
In the EPIC Study, dogs in the
pimobendan group experienced 60 % more time in asymptomatic stage B2 of heart disease and 10 % more life
without CHF signs that impact quality of life (10 % more life
without CHF was calculated based on an estimated lifespan for all small to medium ‑ sized dogs being 12.5 years.